Assessment of disease progression in motor neuron disease


Autoria(s): Winhammar, Jennica M. C.; Rowe, Dominic B.; Henderson, Robert D.; Kiernan, Matthew C.
Contribuinte(s)

R. Love

Data(s)

01/04/2005

Resumo

Motor neuron disease (MND) is characterised by progressive deterioration of the corticospinal tract, brainstem, and anterior horn cells of the spinal cord. There is no pathognomonic test for the diagnosis of MND, and physicians rely on clinical criteria-upper and lower motor neuron signs-for diagnosis. The presentations, clinical phenotypes, and outcomes of MND are diverse and have not been combined into a marker of disease progression. No single algorithm combines the findings of functional assessments and rating scales, such as those that assess quality of life, with biological markers of disease activity and findings from imaging and neurophysiological assessments. Here, we critically appraise developments in each of these areas and discuss the potential of such measures to be included in the future assessment of disease progression in patients with MND.

Identificador

http://espace.library.uq.edu.au/view/UQ:75223

Idioma(s)

eng

Publicador

The Lancet Publishing Group

Palavras-Chave #Clinical Neurology #Amyotrophic-lateral-sclerosis #Unit Number Estimation #Magnetic-resonance Spectroscopy #Placebo-controlled Trial #Inflammatory Demyelinating Polyneuropathy #Respiratory Muscle Strength #Ciliary Neurotrophic Factor #Nasal Inspiratory Pressure #Flail Arm Syndrome #Quality-of-life #C1 #321013 Neurology and Neuromuscular Diseases #730104 Nervous system and disorders
Tipo

Journal Article